Search the Newsreel

MediciNova stock trades steady as pipeline progress contrasts with lower recent revenues

MediciNova (MNOV) stock is trading steadily, reflecting investor focus on its clinical development pipeline despite recent revenue declines. The small-cap biotech's financial profile is shaped by its neurology, autoimmune, and respiratory asset development, with stable R&D spending backed by existing cash reserves. Key asset …

MediciNova reaches 200-patient enrollment in ALS study By Investing.com

MediciNova (NASDAQ:MNOV) has successfully reached its target enrollment of 200 patients in the SEANOBI-ALS study for MN-166 (ibudilast) in treating amyotrophic lateral sclerosis. The study, funded by NIH under the ACT for ALS initiative, is expected to conclude patient follow-ups in early 2027, followed …

Analysts Offer Insights on Healthcare Companies: Medicinova (MNOV), Legend Biotech (LEGN) and AngioDynamics (ANGO)

Three healthcare companies, Medicinova (MNOV), Legend Biotech (LEGN), and AngioDynamics (ANGO), have received bullish ratings from analysts. H.C. Wainwright analysts maintained Buy ratings for all three, with price targets of $10.00 for Medicinova, $65.00 for Legend Biotech, and $19.00 for AngioDynamics, suggesting significant upside …

MediciNova Achieves Full Enrollment in NIH-Funded SEANOBI-ALS Study of MN-166 (Ibudilast) for ALS

MediciNova, Inc. announced the full enrollment of 200 patients in its NIH-funded SEANOBI-ALS study for MN-166 (ibudilast) as a treatment for Amyotrophic Lateral Sclerosis (ALS). This Expanded Access Program allows ALS patients ineligible for clinical trials to receive the investigational drug. Final patient follow-ups …

ALS patients ineligible for trials join MediciNova's 200-person study

MediciNova (NASDAQ: MNOV) has achieved the enrollment target of 200 ALS patients in its NIH-funded SEANOBI-ALS Expanded Access Program, which evaluates MN-166 (ibudilast). This program allows ALS patients ineligible for randomized clinical trials to access the investigational drug. Final patient follow-ups are expected by …

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

MediciNova announced that it has achieved the target enrollment of 200 patients in its SEANOBI-ALS Expanded Access Program, which evaluates MN‑166 (ibudilast) for individuals with amyotrophic lateral sclerosis (ALS) who are not eligible for other clinical trials. This NIH-funded study reflects strong community engagement, …

Why Did Inoviq Ltd (ASX: IIQ) Shares Fall Today?

Inovio Pharmaceuticals (INO) Q1 2026 Earnings Report Highlights Progress and Cash Position

INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights

Inovio (INO) Q1 2026 Earnings Call Transcript

INOVIO to discuss Q1 results and business update in May 13 webcast

INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Inovio Pharmaceuticals Inc (INO) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Resultados financieros de Inovio Pharmaceuticals, Inc. – NASDAQ:INO